Antiphospholipid antibodies can influence the results of clotting tests in as ubset of patients, which can be am ajor obstaclei n monitoring warfarin.Theaim was to determine if point-of-care testing of the International Normalized Ratio (INR) is influenced by antiphospholipid antibodies. We compared 59 patients receiving warfarin forad iagnosis of antiphospholipid antibody syndrome (APS) to 49 patients receiving warfarin foratrial fibrillation to evaluate theconsistencybetween INR results obtained by differentmethods. INR results obtainedbyfinger stick (capillarywhole-blood) andvenipuncture(non-citratedand citrated whole-blood)w erec ompared with our laboratory plasmabased prothrombin timeassay. Fivepatients(8%)with APS and both elevatedanti-β 2 glycoprotein Ilevelsand positive lupus anticoagulantshad non-measurable ProTime 
Introduction
The degree to whichantiphospholipidantibodies influenceINR results is controversial. We (1, 2) and others (3, 4) have demonstratedthat asubset of patients with lupus anticoagulants (LA) have antibodiesthat influencethe prothrombin time(PT)which leads to InternationalNormalizedRatio (INR)results thatdonot accurately reflect the true anticoagulant effect of warfarin.Sanfelippo,etal. (3) estimatedthis to occur in 6.5% of patients based on failureofLA-positivepatients to correct the PT with normal plasma comparedt oL A-negative patients. We (2) found that 19% of patients (12/65) with antiphospholipid antibody syndrome (APS)onwarfarinhad INR results thatoverestimatedthe anticoagulant effect and that of these patients, 11% had INR results thatw ere considered"therapeutic"(INR>2.0), butw ere subtherapeutic by achromogenic factor Xassay. Also, in astudy comparing twodifferent PT assays, Della Va lle et al. (4) found that in 41% (8/17) of LA-positivepatients on warfarin,INR values were significantly higher using arecombinantversus acombined thromboplastin reagent.
In contrast, others (5) (6) (7) (8) have concluded thatINR results can be followedi nL A-positivep atients, as long as LA-sensitive thromboplastins are notusedinPTassays (6) (7) (8) .Ofthe thromboplastin reagents that have beentestedfor sensitivity to LA, Innovin and Thromborel Rhavebeen shown to be influenced by the presence of LA.U sing eightd ifferent thromboplastin reagents withthe InternationalSensitivity Index (ISI) ranging from 1.0to 1.8, Robertetal. (7) reported thatonlyInnovin (ISI =1.10) overestimatedthe INRin14% of LA samples (6/43) . Similarly,Tripodi et al. (8) found that PT assays using Thromborel R(ISI= 1.33) were significantly influenced by LA with6 7% of LA samples (39/58) yielding higher INRresults.
To overcome the difficultiesa ssociatedw ith LA-sensitive thromboplastins, alternativeapproachestomonitoring warfarin for patients with APS have beenproposed (1, 3, 4) . We (1), and Sanfelippo et al.(3) demonstrated that resultsfrom the chromogenic factor Xassaycould provide an alternate method of monitoring the anticoagulant effect of warfarin in patients whohave LA that interfere withthe PT assay. However, the chromogenic factor Xassayisnot readilya vailablefor most clinicalsettings due to the need foras pecializedc oagulation laboratory. Della Va lle et al. (4) concluded that accurate INRresults maybeobtained from combined thromboplastin reagents that permit testing at high plasma dilution, although these reagents aren ot widelyusedfor INRmonitoring.
Point-of-care testing systems, usinge itherr ecombinanto r conventional thromboplastin, arenow availablethrough the use of dry-reagent technology.Anincreasing number of anticoagulation clinics areusing point-of-care instruments for monitoring patients on warfarin.Itisunknown howthis different methodologyfor PT testing will be affectedbysamples frompatients with APS. We conducted this studyt oc omparet he INRr esults obtainedinpatients with APS on warfarin by performing our institution'sp lasma-based method,d ifferent point-of-care testing systems, and the chromogenicfactor Xinorder to determine if antiphospholipid antibodiesi nfluence INRr esults obtainedb y point-of-care testing systems.
Materials andmethods
This wasasingle center,observationalstudy approvedbythe institutional reviewboardand performed in the General Clinical ResearchCenter (GCRC) at Duke University Health System. Informedconsent wasobtained on all patients and the Principles of the Declaration of Helsinki regarding investigations in humans were observed.
Antiphospholipid antibodysyndrome groupand controlgroup
Patients were identifiedt hrough the DukeA nticoagulation Clinic where approximately 600 patients arefollowedfor management of warfarin.Ofthese patients about 10% have adiagnosis of APS and about 30%h avead iagnosis of atrial fibrillation. Forthis study,the APS group included patients whohave had apositivelaboratorytestfor antiphospholipid antibodies and were on warfarin for apastthrombotic event.The control group included patients whoare on warfarin for atrial fibrillation.
Patients were contacted prior to ascheduled appointment for routine monitoring of their INR and asked to have afingerstick performed in addition to the usual venipuncture for the INRresult. Acitrated-blood sample from the venipuncture wassent to the Duke CoagulationLaboratoryfor routine INRtesting usinga plasma-basedm ethod. Warfarin doses were adjustedb yp roviders in the Anticoagulation Clinic basedonthe plasma-based INR result. Fort he Hemochron Signature INR,d isposabler eagentc uvettesf or citrated whole blood and non-citratedw hole blood were used. TheH emochron Signature cuvette usesathromboplastin of rabbit brain origin with an ISI of 1.0. Since these cuvettes do not have internal controls, both anormal and abnormalcontrol made of non-humananimal blood,were performed foreach newbox of cuvettes. Dailyquality control testing was performed on the Hemochron Signature instruments usinga temperature verification cartridge and twol evelso fe lectronic controls. Foreach INR performed using the Hemochron Signature instrument, 50 µ lo fb lood wasp ipettedi nto the cuvette sample well and duplicated on asecondinstrument.
Bloodcollection and coagulation tests
Blood samples collected from asingle venipuncture included adiscard tube,one blood collection tube without additives, and twotubes with 3.8% trisodium citrate. First,b lood collected in the tube without additiveswas used to obtain an INR resultfrom the Hemochron Signature instrument usingc uvettes for noncitrated whole blood. This wasperformed in accordance with our GCRC'ss pecific guidelines for blood collection, although the manufacturerrecommends usingasyringe to collectthe non-citrate whole blood sample. Then, blood collected in acitrated tube wasusedtoobtain an INRresultfrom the Hemochron Signature instrument usingcuvettes for citrated whole blood.
Citrated blood wasalso sent to the Coagulation Laboratory and parallelI NR measurementsw ere obtainedb yap lasmabasedmethodusing an MDA-180 ® analyzer (bioMeriéux,Durham, USA) with Simplastin-HTF (bioMeriéux, Durham, USA), ahuman cell line thromboplastin with an ISI of 1.15. All samples were stored at -70°Cu ntil testing for antiphospholipid antibodies and the chromogenic Factor Xcould be performed.
Assays
Antiphospholipidantibodies including anticardiolipinIgG (cutoff ≥ 11 GPL units/ml)and IgM (cut-off ≥ 9MPL units/ml)antibodies, anti-prothrombin antibodies (cut-off ≥ 10 GAU/ml), and anti-β 2 glycoprotein I( anti-β 2 GPI) antibodies (cut-off>0 .4 GAU/ml) were detected by ELISA using Asserachrom ® kits (providedb yD r. Laura Wo rfolk, DiagnosticaS tago, Asnières, France).
Lupus anticoagulantswere detected by using the diluteRussell'sV iperV enomT ime Screen and Confirm (cut-off ≥ 1.4; Perquik ® LA-Check, bioMérieux, Durham, USA) and also the hexphase assay(cut-off >8seconds;Staclot ® LA 20, Diagnostica Stago)toincrease the sensitivity of detecting LA positivepatients (9) . This wasinaccordance with criteriafor LA detection establishedbythe InternationalSociety of Thrombosis and Haemostasis (10, 11) .
Chromogenic Factor Xl evelsw ere measured on aC oag a Mate MTX ® analyzer,using aDiaPharma ® Factor Xkit (diaPharma,W estChester, USA). INR valuesof2.0 to 3.0 have been found to correlatetochromogenic factor Xlevelsof45% to 24%. (Ortel TL,unpublished data). In this study,chromogenic factor X levels were used as areference againstwhich INRresults from differentmethods were assessed.
Statisticalanalysis
Agreement between INR methodsw as evaluatedb ya" difference plot", knownasaBland-Altmanplot (12, 13) . This graphical method plots the difference between twot ests being compared on the y-axis and the meanofthe twotests on the x-axis. Agreement wasalso evaluatedbycalculating the absolutedifference in INR results between twoI NR methodsa nd using the meanofthis absolute difference to makecomparisons between the twop atient groups. The meana bsoluted ifference wasa lso evaluatedbyINR range and further comparisons between thepatient groups were made by calculating the percentage of the absolute differencefalling within 0.4.Methods were considered to differ clinicallyifthe means of absolute differencesbetween individual methodso fo btaining INRr esults differed by 0.4 or greater.R eproducibility for each point-of-care method was evaluatedbycalculating the mean absolutedifference of duplicateINR results.Comparisons betweenthe twopatient groups were made by using two-sample t-tests for means for continuous variablesand chi-squaretestfor categorical variables.
We also assessedthe utility of using the chromogenic factor Xbycomparing concordant INRresults between allmethods for the INR ranges of <2.0, 2.0 to 3.0, and >3.0 with the corresponding chromogenic factor Xresult.
All statistical analyses were performed using the Statistical Packagefor SAS ® version 9.1(Cary, USA) and figureswere generated using Microsoft 
Results
Between May2003 and March 2004, 59 patients with adiagnosis of APS and 49 with atrial fibrillation participated in this study. Five patients, including threep atients in the atrial fibrillation group and twopatients in the APS group, were excluded because of the inability to obtain blood by finger stick. Additionally, five patients in the APS group had non-measurable INRresults by the ProTime system. Thesef ivep atients were excluded fromt he overallanalysis and arediscussedindetailbelow.
Patient characteristics are summarizedi nT able 1. As expected therew ere differences in age (p<0.0001) and gender (p=0.07),r eflecting an older population with atrial fibrillation and an increased number of womenw ith APS. In general, the mean INR results were slightlyhigherinthe APS group for all methods, with atrend towards statistical significancefor the Pro- Cutoffs:Anti-β 2 GPI (GAU/ml) >0.4; Anti-prothrombin IgG(GAU/ml) ≥ 10; Anticardiolipin IgG(GPL units/ml) =11; Anticardiolipin IgM(MPL units/ml) ≥ 9; dRVVT Confirm ≥ 1.4; Staclot ® LA >8seconds (difference between the twoclotting times) Therapeutic range: Chromogenic factor X24% -45% (Range forINR values3.0-2.0).
Time (p=0.07) and the plasma-based (p=0.05) INR results between the twogroups. Antiphospholipidantibodies have beenreported to vary over time in patients; therefore, patients were testedatthe timeofenrollment using several commercially availableassays. To verify thato ur groups differedf or antiphospholipid antibodies, both APS and atrial fibrillation groups were tested(Table1). In the APS group, 32 patients were positive for at leastone test (61%) compared to 12 patients in the atrial fibrillation group (26%). Patients in the APS group were morelikelytohaveLA(p<0.0001), anti-β 2 GPI( p<0.0001), and anticardiolipinI gG (p<0.04) than patients in the atrial fibrillation group. Of the patients in the AF group whodid have antiphospholipid antibodies, most hadeither low-titera nticardiolipin IgM (n=4; range 10-22 MPL) or IgG antibodies (n=7; range 15-26 GPL).
In five patients with APS,the ProTime system would not give an INR result, whereas the plasma-based method reported INR valuesranging from 2.8to4.5 (Table 2 ). In these five APSpatients, there were no technical difficultiesinthe procedure, yet the ProTime instrument gave an errormessage foreach of these patients, indicating thatthe PT for the control levelIdid not normalizeasexpected. This error indicatesthat the internal control channel in the ProTime cuvette has failedtofallinto the predeterminedr angea nd an erroneous INRr esulti ss uppressed. For these five patients, agreement betweenthe plasma-basedINR resultsw as less with the Hemochron Signature (non-citrate) than witht he Hemochron Signature (citrate) system. Thep lasmabasedI NR results appearedt oc orrelate with the chromogenic Factor Xactivity.
Excluding the five patients with APS describedabove,reproducibility for each point-of-care system wassimilarfor the two patient groups. The meanabsolutedifference of duplicateINR results were as follows: ( 1 Agreement between theplasma-based method and the pointof-care systems wasassessedbycomparing the absolute difference between INR values. Table3shows the means (±SD) for the absolute difference betweenINR valuesfor each method being comparedbetween the APS and atrial fibrillation patient groups. The twopatient groups were significantly different for the mean absoluted ifferences between INR valuesf or the plasma-based and the ProTime methods(p=0.02). MeanINR versusdifference plotso ft he plasma-baseda nd ProTime methods showg raphically thatt he majority of the differencesb etween the two methodsfallwithin ±0.4 for the atrial fibrillation group ( Fig. 1; top)compared to agreater numberofthe differencesfalling outside of ±0.4 for the APS group ( Fig. 1; b ottom) . The differences for both groups aredistributedevenlyaround zero with atendency for greater differences observed with increasing INR.
Agreement between theplasma-based method and the pointof-care systems wasalso evaluatedbyINR range, usingthe plasma-basedINR results to establish theranges ( Table 4 theAPS and AF group, the chromogenic factor Xresults were in agreement forthe INRresults <2.0. Forthe INRrangeof2.0 to 3.0, the agreement wasgood for both groups, with only2sub-jects in the APS group having subtherapeutic chromogenic factor Xresults at 47%and 48%. Forthe INRrange>3.0, the agreement with the chromogenic factor Xw as poor.O nly2 /9 APS subjectsh ad concordantc hromogenic factor Xr esults at 19% and 21%; whereas,onlyone AF subjectdid not showconcordanceand interestinglyhad alow positiveanticardiolipin IgG.
Discussion
Warfarin is effectivei nd ecreasing recurrent thrombosis in patients with APS; however, the optimaltarget INR is controversial (14) (15) (16) (17) . This controversymay be in partbedue to the potential influenceofantiphospholipidantibodies on the thromboplastin reagents used in PT assays (1) (2) (3) (4) (5) (6) (7) (8) .Inpreviousstudies, we found thatINR results do not accuratelyreflect the true anticoagulant effect of warfarin in asubset of LA-positivepatients (1, 2). We hypothesizedt hat the dry-reagent technology used in pointof-care testing of the INRwould not be influenced by antiphospholipid antibodies. Several prospective studiesh avec ompared point-of-care testing systems to plasma-basedm ethods (18) (19) (20) (21) (22) . In these studies, agreement of INR results ranged from 60%to90% within ±0.5 and 89% within ±0.4 INRunits.Intwo other studies, different point-of-care testing systems were compared to several differentt hromboplastin reagents using the plasma-basedP T assays (23, 24) .Both studies found that the different thromboplastins used on the same samples did not yield equivalent INR results with the high-sensitivity thromboplastins (low ISI) giving INR results with less variability thenthe low-sensitivity thromboplastins (high ISI).The performanceofthe point-of-caretesting systems in these twostudieswas felttobesatisfactory. None of these studies evaluatedpatients with APS.
To our knowledge this is the first studytoevaluate the use of point-of-care testing systems in patients with adiagnosis of APS. Ourstudy recruitedpatients on the basis of their diagnosis in the Anticoagulation Clinic.Atthe timeofenrolment, 61% of the patients in the APS group and 26% of patients in the atrial fibrillation group were positive for oneormore of the antiphospholipid antibody tests. However, in the atrial fibrillation group, only 3p atients were LA positive (7%) versus2 6i nt he APS group (50%). In addition, although 11 patients with atrial fibrillation had elevatedanticardiolipin antibody levels, nonehad atiter>30 GPL, and none had elevateda nti-β 2 -glycoprotein Io ra ntiprothrombin antibody levels. Givent he fact thata ntiphospholipid antibodiesa re moref requently detectedi no lderp atient populations,wefeltthat analyzing the data by group wasappropriate.
In 8% of the APS patients, the ProTime system wasunable to determine an INR result(Table2). In these patients, the control levelIchannel on the ProTime cuvette did not normalize. This (Table 4) .
Comparisons between the twog roups were alsom ade by evaluating the agreement of the chromogenicf actor Xr esults with concordantINR results (Table 5 ). The chromogenicfactor Xh ad similar agreement forb oth groups for the INRr esults ranging <2.0 and between2.0 to 3.0. The most striking finding wasthat 9/11 of subjects in the APS group had chromogenic factor Xresults thatw ere in the therapeutic rangeeventhough the corresponding INRresults were >3.0.
The advantages of point-of-care testing for the INR(25) must be weigheda gainst the decreased agreement between different methods. In ourstudy,the ISI for the reagent used in the plasmabasedm ethod( Simplastin-HTF ® ,I SI of 1.15)a nd for the ProTime system(driedhuman recombinant thromboplastin, ISI of approximately 1.0) were similar. As withplasma-based methods, there have beenr eportso fi ncorrect calibrations of the ISI for point-of-care instruments (26) . However, the reasonf or the greater difference observed forthe ProTime system in the APS group maybesimilartothe proposedreason fordifferences observed with Innovin and Thromborel Rinpreviousstudies (7, 8) . Tripodietal. (8) concluded thatitmay be the phospholipid composition that is responsible for the degree of influencethat LA has on aparticularreagent.
We found good agreementbetween ourinstitution'splasmabasedmethodand the ProTime system for atrial fibrillation patients, butnot as good for APS patients. We were unable to identifywhetherthe antiphospholipid antibody type or titer accounted for the differences observedbetween the plasma-based and the ProTime methods. However, we did find that in 8% of the APS patients with both elevateda nti-β 2 GPIa ntibodies and positive for LA, the control levelIwasunable to normalize whichmay be due to interferencefrom antiphospholipid antibodies(Table2). This subseto fp atients also hadw ide variationsi nI NR results obtained by the Hemochron Signature (citrate and non-citrate) systemwhen comparedwith the plasma-based method.
The results from thisstudy suggest thatthe ProTime system will not reportINR results for some APSpatients. This confirms the finding from published reports of asubset of patients having antiphospholipid antibodies whichi nterfere with INRr esults. Before implementing point-of-care testing systems to test the INR in APS patients, we recommend evaluating for agreement againstathromboplastin reagent with less sensitivity to antiphospholipid antibodies. Forasubset of APS patients an alternative method of monitoring the anticoagulation effect of warfarins uch as the chromogenic factor X( 1) or using combined thromboplastin reagents (4) maybenecessary.
